ArticleOphthalmology science2026
Oral Tonabersat Connexin-43 Modulator for Diabetic Macular Edema with Good Vision (DRCR Retina Network Protocol AN).
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Evaluate oral tonabersat, a connexin-43 hemichannel modulator, on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good vision. Design: Phase II randomized, double-masked clinical trial. Participants: One hundred twenty-nine adults with CI-DME and visual acuity (VA) 20/32 or better, from 24 US sites. Intervention: Participants randomly assigned 1:1- to 80-mg tonabersat (N = 64, [71 eyes]) or placebo (N = 65, [73 eyes]) for 6 months. Main Outcome Measures: Change in OCT CST. Results: Overall, 37% of participants were female, with a mean age of 63 years. In tonabersat and placebo groups, respectively, the baseline mean CST was 359 and 362 μm; the mean (standard deviation [SD]) change in CST from baseline to 6 months was -15 (55) μm and +5 (51) μm; (adjusted mean difference: -16 [95% confidence interval (CI), -34 to 2], Conclusions: There was no statistically significant improvement in CST at 6 months in the tonabersat versus placebo groups. However, a post hoc analysis limiting anti-VEGF impact demonstrated significant benefit in the tonabersat group. Aside from increased dizziness, consistent tonabersat safety concerns were not identified. Given findings consistent with a potentially favorable biologic effect of tonabersat, further research into the role of the inflammasome in DME is warranted. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.